Comparison of deferasirox and deferoxamine effect on liver enzyme activities and ferritin level in patients with beta-thalassemia

摘要

Background and objective: Patients on blood transfusion may develop complicationsrelated to iron overload and the effects of chelating agents (drugs), which adverselyaffect the liver in thalassemia, which is a genetic blood disorder of hemoglobin synthesisthat causes severe anemia. This study aimed to assess the effect of deferasirox anddeferoxamine drugs on liver enzyme activities (aspartate transaminase, alaninetransaminase, and alkaline phosphatase), and serum ferritin level in β_thalassemicpatients.Methods: This study was carried out in Erbil city from October 2017 to February 2018.Blood specimens were collected in Hawler thalassemia center and Raparin hospital. Thesamples included 105 individuals; 70 β-thalassemic patients (35 treated by deferasirox asgroup A and 35 treated by deferoxamine as group B), and 35 healthy individuals (controlgroup C).Results: The serum aspartate transaminase and alkaline phosphatase activities inβ-thalassemic patients were higher than that of controls. The serum alanine transaminaseactivity in the patients' groups showed non-significant elevation than that of controls. Theserum ferritin level in the patients was significantly higher than that of controls.Conclusion: Our finding showed that both deferasirox and deferoxamine drugs affect liverenzymes and increase ferritin level.